SHERIDAN, WYOMING -- August 14, 2026 -- Basilea Pharmaceutica AG has received an additional USD 5.4 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. The funds will support continued development of ceftibuten-ledaborbactam etzadroxil, an oral antibiotic candidate combining a beta-lactam antibiotic with a beta-lactamase inhibitor. The compound is being studied for complicated urinary tract infections, including pyelonephritis, caused by drug-resistant bacteria. This latest tranche brings total BARDA support for the program to USD 30.8 million.
Federal Backing Continues to Build Around the Program
BARDA's involvement dates back to a contract that could ultimately provide up to USD 172 million in non-dilutive funding, though roughly USD 14 million of that figure predates the agreement's transfer to Basilea. The steady release of funds in tranches gives the Swiss biopharmaceutical company a degree of financial support as it moves the candidate through later-stage development. For investors and industry observers, continued government backing offers a measure of validation for a therapeutic area that has struggled to attract sufficient private capital in recent years.
Basilea's chief executive, David Veitch, described the funding as reinforcing a collaborative relationship with BARDA aimed at bringing forward new anti-infective treatments for patients with severe infections. He characterized the support as helping the company push ahead with development of ceftibuten-ledaborbactam etzadroxil, noting that the drug candidate is intended to address an unmet need for an oral treatment option targeting complicated urinary tract infections caused by multidrug-resistant gram-negative bacteria.
How the Combination Therapy Is Designed to Work
Ceftibuten-ledaborbactam etzadroxil pairs ledaborbactam etzadroxil, an orally bioavailable prodrug of a boronic acid-based beta-lactamase inhibitor, with ceftibuten, a cephalosporin-class antibiotic already approved in the United States for respiratory infections and used elsewhere for urinary tract infections. Beta-lactamase inhibitors work by blocking enzymes that many gram-negative bacteria produce to resist standard antibiotics, effectively restoring the activity of the paired beta-lactam drug.
Laboratory and animal studies cited by Basilea indicate that ledaborbactam etzadroxil restores ceftibuten's activity against strains of Enterobacterales bacteria that express extended-spectrum beta-lactamases, class C cephalosporinases, and certain carbapenemases, including KPC and OXA-48 variants. The candidate has also shown activity against multidrug-resistant Enterobacterales in these preclinical settings. The FDA has granted the program Qualified Infectious Disease Product and Fast Track designations for both complicated and uncomplicated urinary tract infection indications. The drug remains investigational and is not approved for commercial use in any country.
A Persistent Gap in Oral Treatment Options
Complicated urinary tract infections, including pyelonephritis, rank among the most common bacterial infections encountered in both hospital and outpatient settings. Rising resistance among the bacteria responsible has narrowed the pool of effective oral antibiotics available to clinicians. Currently, no approved oral beta-lactam antibiotic or beta-lactam/beta-lactamase inhibitor combination is effective against Enterobacterales strains that express the specific resistance enzymes targeted by Basilea's candidate. For hospital procurement teams and infectious disease specialists, that gap has meant relying more heavily on intravenous therapies or broader-spectrum agents, raising both cost and administration complexity for patients who might otherwise be treated on an outpatient basis.
Company Position and Development Pipeline
Basilea, founded in 2000 and based in Switzerland, already markets two hospital-use products: Cresemba, for invasive fungal infections, and Zevtera, for bacterial infections. The company also maintains a pipeline of preclinical and clinical anti-infective programs beyond the BARDA-supported candidate. Listed on the SIX Swiss Exchange under the ticker BSLN, Basilea positions itself within a narrow field of biopharmaceutical companies still actively developing new antibacterial and antifungal therapies, a segment that has seen reduced private investment despite persistent clinical need.
For buyers and health system stakeholders tracking the antibiotic development landscape, continued BARDA funding offers a signal of program continuity rather than a guarantee of eventual approval. Ceftibuten-ledaborbactam etzadroxil remains subject to further clinical evaluation before any regulatory filing could occur.
For more information on Basilea's anti-infective portfolio and corporate updates, visit https://www.basilea.com.